Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update. “With CNSide, our paradigm-changing neuro-oncology test that uses cerebrospinal fluid for diagnosing and monitoring patients with brain metastases, we are reporting strong sequential quarter volume growth, primarily driven by data generated with our acad

Biocept Reports Third Quarter 2021 Financial Results

Biocept Inc (NASDAQ:BIOC) has announced the publication of a study showing that the addition of Switch-Blocker technology to common PCR-based liquid biopsy assays significantly increased sensitivity in detecting rare cancer mutations. The abstract was published in the November 2021 issue of the “Journal of Molecular Diagnostics.

Biocept says study shows its Switch-Blocker technology enhances performance of PCR-based liquid biopsy assays in detecting rare cancer mutations

SAN DIEGO--(BUSINESS WIRE)--Published abstract shows Biocept's Switch-Blocker technology increases the sensitivity of liquid biopsy assays for detecting rare cancer mutations.

Study Shows Biocept's Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Date/Time: Monday, November 15, 4:30 p.m. ET / 1:30 p.m. PT   P

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #LD_Micro--Biocept to present at LD Micro Main Event

Biocept to Present at the LD Micro Main Event on October 13

Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord. Between 10% and 30% of cancer patients, and a much higher percentage of late-stage cancer patients will develop brain or spinal cord metastasis.

Biocept: A New Diagnostic Approach to Improve the Lives of Cancer Patients

Biocept Inc has implemented its COVID-19 testing services at more than 30 community college campuses across California.  Also, the company said it is streamlining the testing and tracking process for administrators, and allowing students and staff to easily schedule and complete COVID-19 testing.

Biocept implements COVID-19 testing services at more than 30 community college campuses across California

SAN DIEGO--(BUSINESS WIRE)--Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.

Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic

Boxlight

Ebang International Holdings

eMagin

Mind Medicine MindMed

Exela Technologies

These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared first on InvestorPlace.

7 of the Best Penny Stocks to Buy Coming Into Year-End

SAN DIEGO--(BUSINESS WIRE)--Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

SAN DIEGO--(BUSINESS WIRE)--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows: H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning Monday, September 13, 2021 at 4:00 a.m. Eastern time (1:00 a.m. Pacific time). Op

Biocept to Present at Four Virtual Investor Conferences in September

Biocept Inc (NASDAQ:BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.

Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay

Biocept Inc told investors that its cerebrospinal fluid assay CNSide had been shown to be able to detect markers of a complication of non-small cell lung cancer (NSCLC), which could mean targeted treatment that would allow patients' lives to be extended. More than 198,000 people are diagnosed with NSCLC each year, said Biocept, and an estimated 3-9% of those will develop leptomeningeal carcinomatosis (LMC), where the cancer spreads to the membranes surrounding the brain and spinal cord.

Biocept says a study of its cerebrospinal fluid assay CNSide shows potential use for cancer treatment

The shares of Biocept Inc (NASDAQ: BIOC) increased by over 20% pre-market. This is why it happened.

Biocept Shares Increase Over 20% Pre-Market: Why It Happened

SAN DIEGO--(BUSINESS WIRE)--Study shows Biocept's CNSide assay detects and analyzes tumor cells in lung cancer patients, improving treatment decisions that may extend life.

Biocept's CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Biocept Inc (NASDAQ: BIOC) reported its second-quarter revenues of $12 million, compared to a mere $917,471 a year ago, but sharply missing the consensus of $17.76 million. The revenue growth is attributable to RT-PCR COVID-19 testing, as only $926,000 in revenue came from oncology testing.

Biocept Stock Drops Despite Clocking Q2 Sales Of $12M

Biocept Inc (NASDAQ:BIOC) reported positive net income for the first half of 2021 as revenues rose due to the increased use of the firm's COVID-19 RT-PCR  tests, notably in the first quarter. In the six months to June 30 this year, the diagnostics group posted a net income of  $772,000 compared to a net loss of $14.8 million in the same period of 2020 on revenue of $29.8 million, a large increase from the revenue figure of $2.4 million seen in the first half of 2020.

Biocept reports profitability for the first half on back of increased COVID-19 testing

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2021 and provides a business update. “We are reporting profitability for the first half of 2021 on revenues of nearly $30 million driven by RT-PCR COVID-19 testing,” said Michael Nall, Biocept's President and CEO. “Revenues of $12.0 million for the quarter reflect the anticipated sequential quart

Biocept Reports Second Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Date/Time: Monday, August 16, 4:30 p.m. ET / 1:30 p.

Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021

Biocept Inc. said it has appointed David Karlander as senior vice president of Commercial Operations.

Biocept appoints David Karlander as senior vice president of Commercial Operations

SAN DIEGO--(BUSINESS WIRE)--Biocept Names David Karlander Senior Vice President of Commercial Operations.

Biocept Names David Karlander as Senior Vice President of Commercial Operations

Biocept Inc (NASDAQ: BIOC) received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs).  Reimbursement decision expands access to testing used to provide information to guide targeted treatment options for patients with breast cancer.

Medicare Issues Coverage Determination For Biocept's Target Selector Assay For Breast Cancer

Biocept Inc (NASDAQ:BIOC) (FRA:B003) said it has received a positive final Local Coverage Determination (LCD) from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program (MolDx), which will expand Medicare coverage for use of Biocept's Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs). The company said the reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer.

Biocept wins approval for expanded Medicare coverage for its Target Selector assay to detect cancer biomarkers

SAN DIEGO--(BUSINESS WIRE)-- #breastcancer--Biocept receives Medicare coverage for breast cancer assay to detect and analyze HER2 biomarker and announces CNSide and COVID-19 testing updates.

Medicare Issues Local Coverage Determination for Biocept's Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

News for Biocept Stock (BIOC)